Development
Maximize ROI for each program
- Leverage established Phase III safety database for “SNAC” and eligen™ technology
- Leverage patent protection for existing and new EMISPHERE® delivery agents
- Minimize risk prior to potential partnership
- Evaluate cost benefit based on market potential, ease of manufacture, etc.
Accelerate commercialization potential based on broad application of eligen™ technology
Develop multiple programs
- Extent of development based on necessary synergies (using big pharma for design and execution)
- Continue product development until improved valuation of a product candidate is realized
- Pursue multiple feasibility arrangements for eventual conversion to fully funded licensing programs
Business Strategy for 2003